Sri Krishna Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 15.00 Cr
- Paid Up Capital ₹ 11.92 Cr
- Company Age 50 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 287.16 Cr
- Satisfied Charges ₹ 184.84 Cr
- Revenue Growth -3.35%
- Profit Growth -52.42%
- Ebitda -34.08%
- Net Worth 1.61%
- Total Assets 2.41%
About Sri Krishna Pharmaceuticals
Sri Krishna Pharmaceuticals Limited (SKPL) is a leading Public Limited Indian Non-Government Company incorporated in India on 26 September 1974 and has a history of 50 years and four months. Its registered office is in Hyderabad, Telangana, India.
The Corporate was formerly known as Sri Krishna Pharmaceuticals Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 15.00 Cr and a paid-up capital of Rs 11.92 Cr.
The company currently has active open charges totaling ₹287.16 Cr. The company has closed loans amounting to ₹184.84 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Sri Krishna Pharmaceuticals Limited India are Nikhil Pandey as Cfo, Kalluru Manaswini as Company Secretary, and Kalluru Manaswini as Company Secretary. Venkatakrishna Vempalli, Muri Madhusudhan, Pranesh Mathur, and Three other members serve as directors at the Company.
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U24230TG1974PLC001790
- Company No.
001790
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
26 Sep 1974
- Date of AGM
31 Jul 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
What products or services does Sri Krishna Pharmaceuticals Limited offer?
Sri Krishna Pharmaceuticals Limited offers a wide range of products and services, including Antipyretic Medication, Paracetamol Tablets, Crocin Advance Tablet, Crocin Tablets.
Who are the key members and board of directors at Sri Krishna Pharmaceuticals?
Executive Team (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Venkatakrishna Vempalli  | Managing Director | 15-Oct-1997 | Current |
| Nikhil Pandey | CFO | 14-Oct-2024 | Current |
| Kalluru Manaswini | Company Secretary | 26-Dec-2023 | Current |
Board Members (5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Pranesh Mathur | Whole-Time Director | 17-Feb-2014 | Current |
| Muri Madhusudhan | Additional Director | 24-Sep-2024 | Current |
| Sunitha Reddivari | Director | 01-Feb-2023 | Current |
| Venkata Vempalle | Whole-Time Director | 26-Sep-1974 | Current |
| Venkateswar Sarvepalli | Director | 31-Oct-2014 | Current |
Financial Performance of Sri Krishna Pharmaceuticals.
Sri Krishna Pharmaceuticals Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 3.35% decrease. The company also saw a substantial fall in profitability, with a 52.42% decrease in profit. The company's net worth moved up by a moderate rise of 1.61%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sri Krishna Pharmaceuticals?
In 2023, Sri Krishna Pharmaceuticals had a promoter holding of 89.09% and a public holding of 10.90%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Isha Arogya Private LimitedVenkata Vempalle is a mutual person
Clonz Biotech Private LimitedVenkatakrishna Vempalli, Pranesh Mathur and 1 more are mutual person
Sri Krishna Biofert Private LimitedVenkatakrishna Vempalli and Venkata Vempalle are mutual person
Charges (Loans)
₹287.16 Cr
₹184.84 Cr
Charges Breakdown by Lending Institutions
- Others : 157.00 Cr
- Axis Bank Limited : 85.16 Cr
- Citi Bank N.A. : 45.00 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 28 Mar 2024 | Others | ₹30.00 Cr | Open |
| 26 Apr 2021 | Citi Bank N.A. | ₹9.00 Cr | Open |
| 30 Mar 2021 | Others | ₹10.00 Cr | Open |
| 07 Jan 2021 | Others | ₹77.00 Cr | Open |
| 22 Oct 2018 | Others | ₹40.00 Cr | Open |
How Many Employees Work at Sri Krishna Pharmaceuticals?
Sri Krishna Pharmaceuticals has a workforce of 1459 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sri Krishna Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sri Krishna Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
